A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Recruiting

Phase 3

EYP-1901A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Sponsor:

EyePoint Pharmaceuticals, Inc.

Code:

NCT06683742

Conditions

Wet Age Related Macular Degeneration

wAMD

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

EYP-1901

Aflibercept (2.0 mg)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-02. This information was provided to ClinicalTrials.gov by EyePoint Pharmaceuticals, Inc. on 2025-08-06.